Motion sickness in migraine sufferers

Bibliography

• IRWIN JA: The pathology of sea-sickness. Lancet (1881) 2:907–909.
   Google Scholar
• MONEY KE: Motion sickness. Physiological Reviews (1970) 50(1):1–39.
   PubMed Web of Science ®Google Scholar
• HETTLINGER LJ, KENNEDY RS, MCCAULEY ME: Motion and human performance. In: Motion and Space Sickness. Crampton GA, CRC Press, Boca Raton, FL, USA (1990):411–440.
   Google Scholar
• GRAYBIEL A, WOOD CD, MILLER EF, CRAMER D: Diagnostic criteria for grading the severity of acute motion sickness. Aerospace Medicine (1968) 39(5):453–5.
   PubMedGoogle Scholar
• TURNER M, GRIFFIN MJ: Motion sickness in public road transport: passenger behavior and susceptibility. Ergonomics (1999) 42(3):444–461.
   PubMed Web of Science ®Google Scholar
• GRUNFELD E, GRESTY MA: Relationship between motion sickness, migraine and menstruation in crew members of a 'round the world' yacht race. Brain Res. Bull. (1998) 47(5):433–436.
   PubMed Web of Science ®Google Scholar
• DOBIE T, MCBRIDE D, DOBIE T JR, MAY J: The effects of age and sex on susceptibility to motion sickness. Aviat. Space Envrion. Med. (2001) 72(1):13–20.
   PubMedGoogle Scholar
• YATES BJ, MILLER AD, LUCOT JB: Physiological basis and pharmacology of motion sickness: an update. Brain Res. Bull. (1998) 47(5):395–406.
   PubMed Web of Science ®Google Scholar
• GRAYBIEL A, KNEPTON J: Sopite syndrome: a sometimes sole manifestation of motion sickness. Aviat. Space Environ. Med. (1976) 47(8):873–882.
   PubMedGoogle Scholar
• KAYAN A, HOOD JD: Neuro-otological manifestations of migraine. Brain (1984) 107(Pt 4):1123–1142.
   PubMed Web of Science ®Google Scholar
• FLEMING JB, AMOS AJ, DESMOND RA: Migraine aura without headache: prevalence and risk factors in a primary eye care population. Optometry (2000) 71(0:381–389.
   PubMedGoogle Scholar
• DRUMMOND PD: Triggers of motion sickness in migraine sufferers. Headache (2005) 45(6):653–656.
   PubMed Web of Science ®Google Scholar
• TURNER M, GRIFFIN MJ, HOLLAND I: Airsickness and aircraft motion during short-haul flights. Aviat. Space Environ. Med. (2000) 71(12):1181–1189.
   PubMed Web of Science ®Google Scholar
• STANNEY KM, HALE KS, NAHMENS I, KENNEDY RS: What to expect from immersive virtual environment exposure: influences of gender, body mass index, and past experience. Hum. Factors (2003) 45(3):504–520.
   PubMed Web of Science ®Google Scholar
• •Exposure to immersive virtual environment results in significant discomfort symptoms to the majority of subjects exposed. Important implications for future virtual technology
   Google Scholar
• PARK AH, HU S: Gender differences in motion sickness history and susceptibility to optokinetic rotation-induced motion sickness. Aviat. Space Environ. Med. (1999) 70(11):1077–1080.
   PubMedGoogle Scholar
• WEICHENTHAL L, SOLIZ T: The incidence and treatment of prehospital motion sickness. Prehosp. Emerg Care (2003) 7(4):474–476.
   PubMedGoogle Scholar
• WRIGHT MS, BOSE CL, STILES AD: The incidence and effects of motion sickness among medical attendants during transport. J. Emerg-. Med. (1995) 13(1):15–20.
   PubMedGoogle Scholar
• FORSTBERG J, ANDERSSON E, LEDIN T: Influence of different conditions for tilt compensation on symptoms of motion sickness in tilting trains. Brain. Res. Bull. (1998) 47(5):525–535.
   PubMed Web of Science ®Google Scholar
• LERMAN Y, SADOVSKY G, GOLDBERG E, KEDEM R, PERITZ E, PINES A: Motion sickness-like syndrome among tank simulator drivers. Isr. J. Med. Sci. (1992) 28(8-9):610–615.
   PubMedGoogle Scholar
• BAYAZIT Y, YILMAZ M, MUMBUC S, KANLIKANA M: Assessment of migraine-related cochleovestibular symptoms. Rev. Laryngol. Otol. RhinoL (2001) 122(2):85–88.
   PubMedGoogle Scholar
• NEUHAUSER H, LEOPOLD M, VON BREVERN M et aL: The interrelations of migraine, vertigo, and migrainous vertigo. Neurology (2001) 56(4):436–441.
   PubMed Web of Science ®Google Scholar
• ••Definition of a unique migraine syndrome,migrainous vertigo, is provided.
   Google Scholar
• LEE H, SOHN SI, JUNG DK et al.: Migraine and isolated recurrent vertigo of unknown cause. Neurol. Res. (2002) 24(7):663–665.
   PubMed Web of Science ®Google Scholar
• MARCUS DA, WHITNEY SL, FURMAN JM: Treatment of migrainous vertigo. Expert. Rev. Neurotherapeutics (2003) 3(3):307–316.
   PubMedGoogle Scholar
• LANZI G, BALOTTIN U, FAZZI E, ROSANO FB: The periodic syndrome in pediatric migraine sufferers. Cephalalgia (1983) 3\(Suppl. 1):91–93.
   Google Scholar
• ABU-ARAFEH I, RUSSELL G: Paroxysmal vertigo as a migraine equivalent in children: a population-based study. Cephalalgia (1995) 15(1):22–25.
   PubMed Web of Science ®Google Scholar
• TAKEDA N, MORITA M, HORII A, NISHIIKE S, KITAHARA T, UNO A: Neural mechanisms of motion sickness. J. Med. Invest. (2001) 48(1-2):44–59.
   PubMedGoogle Scholar
• JAVID FA, NAYLOR RJ: The effect of serotonin and serotonin receptor antagonists on motion sickness in Suncus murinus. PharmacoL Biochem. Behav. (2002) 73(4):979–989.
   PubMed Web of Science ®Google Scholar
• ••Exposure to serotonin-active drugs resultsin reduced emesis in rodents exposed to motion-sickness provocation.
   Google Scholar
• BURSTEIN R, COLLINS B, BAJWA Z, JAKUBOWSKI M: Triptan therapy can abort migraine attacks if given before the establishment or in the absence of cutaneous allodynia and central sensitization: clinical and preclinical evidence. Headache (2002) 42(5):390–391.
   Google Scholar
• NEUHAUSER H, RADTKE A, VON BREVERN M, LEMPERT T: Zolmitriptan for treatment of migrainous vertigo: a pilot randomized placebo-controlled trial. Neurology (2003) 60(5):882–883.
   PubMed Web of Science ®Google Scholar
• DRUMMOND PD: Motion sickness and migraine: optokinetic stimulation increases scalp tenderness, pain sensitivity in the fingers and photophobia. Cephalalgia (2002) 22(2):117–124.
   PubMed Web of Science ®Google Scholar
• DRUMMOND PD, GRANSTON A: Facial pain increases nausea and headache during motion sickness in migraine sufferers. Brain (2004) 127(3):526–534.
   PubMedGoogle Scholar
• •Increased trigeminal activity through application of painful temple stimulation increased susceptibility of migraineurs to motion sickness provocation. These data indicate a synergistic effect between activation of pain and vestibular centers.
   Google Scholar
• FURMAN JM, MARCUS DA, BALABAN C: Migrainous vertigo: development of a pathogenetic model and structural diagnostic interview. Curr. Opin. NeuroL (2003) 16(1):5–13.
   PubMed Web of Science ®Google Scholar
• CHINN HI, SMITH PK: Motion sickness. PharmacoL Rev. (1955) 7(1):33–82.
   PubMed Web of Science ®Google Scholar
• ••
   Google Scholar
• BALABAN CD, YATES BJ: Vestibulo-autonomic interactions: a teleologic perspective. In: Springer Handbook of Auditory Research: The Vestibular System. Highstein SN, Fay RR, Popper AN (Eds), Springer-Verlag, New York, NY, USA (2004):286–342.
   Google Scholar
• BALABAN CD: Vestibular autonomic regulation. Curr. Opin. NeuroL (1999) 12(1):29–33.
   PubMed Web of Science ®Google Scholar
• BALABAN CD, THAYER JF: Neurological bases for balance-anxiety links. J. Anxiety Disord. (2001) 15(1-2):53–79.
   PubMed Web of Science ®Google Scholar
• MARANO E, MARCELLI DISTASIO E et al.: Trigeminal stimulation elicits a peripheral vestibular imbalance in migraine patients. Headache (2005) 45(4):325–331.
   Google Scholar
• MENÉTREY D, BASBAUM Al: Spinal and trigeminal projections to the nucleus of the solitary tract: a possible substrate for somatovisceral and viscero-visceral reflex activation. J. Comp. NeuroL (1987) 255(3):439–450.
   PubMed Web of Science ®Google Scholar
• CRAIG AD: How do you feel? Interoception: the sense of the physiological condition of the body. Nat. Rev. Neurosci. (2002) 3(8):655–666.
   PubMed Web of Science ®Google Scholar
• MARCUS DA, FURMAN JM: Prevention of motion sickness with rizatriptan: a double-blind, placebo-controlled pilot study. Med. Sci. Monit. (in press).
   Google Scholar
• ••First report in the literature documentingthe ability of a triptan to prevent the development of motion sickness in a subgroup of susceptible migraineurs.
   Google Scholar
• MARCUS DA, KAPELEWSKI C, RUDY TE, JACOB RG, FURMAN JM: Diagnosis of migrainous vertigo: validity of a structured interview. Med. Sci. Monit. (2004) 10(5):CR197-CR201.
   Google Scholar
• •Validated structured interview to screen for migrainous vertigo.
   Google Scholar
• NAPIER C, STEWART M, MELROSE H, HOPKINS B, MCHARG A. WALLIS R: Characterization of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur. j Pharmacol. (1999) 368(2–3):259–268.
   Google Scholar
• TFELT-HANSEN P, DE VRIES P, SAXENA PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs (2000) 60(6):1259–1287.
   PubMed Web of Science ®Google Scholar
• PASCUAL J, DEL ARCO C, ROMON T,DEL OLMO E, CASTRO E, PAZOS A: Autoradiographic distribution of [3H]sumatriptan-binding sites in human postmortem brain. Cepha/a/gia (1996) 16(5):317–322.
   PubMed Web of Science ®Google Scholar
• HOSKIN KL, LAMBERT GA, DONALDSON C, ZAGAMI AS: The 5-hydroxytryptamine1/1,/1 receptor agonists eletriptan and naratriptan inhibit trigeminovascular input to the nucleus tractus solitarius in the cat. Brain Res. (2004) 998(1):91–99.
   PubMed Web of Science ®Google Scholar
• BOERS PM, DONALDSON C, ZAGAMI AS, LAMBERT GA: Naratriptan has a selective inhibitory effect on trigeminovascular neurones at central 5-HT1A and 5-HT1B/D receptors in the cat: implications for migraine therapy. Cephalalgia (2004) 24(2):99–109.
   PubMed Web of Science ®Google Scholar
• JOHNSTON AR, MURNION B, MCQUEEN DS, DUTIA MB: Excitation and inhibition of rat medial vestibular nucleus neurones by 5-hydroxytryptamine. Exp. Brain Res. (1993) 93(2):293–298.
   PubMed Web of Science ®Google Scholar
• AMANO T, AKBAR M, MATSUBAYASHI H, SASA M: Inhibitory effects of tandospirone, a 5-HT1A agonist, on medial vestibular nucleus neurons responding to lateral roll tilt stimulation in rats. Brain Res. (2001) 910(1-2):195–198.
   PubMed Web of Science ®Google Scholar
• KISHIMOTO T, YAMANAKA T, AMANO T, TODO N, SASA M: 5-HT1A receptor-mediated inhibition of lateral vestibular nucleus neurons projecting to the abducens nucleus. Brain Res. (1994) 644(1):47–51.
   PubMed Web of Science ®Google Scholar
• GOLDING JF: Motion sickness susceptibility questionnaire revised and its relationship to other forms of sickness. Brain Res. Bull. (1998) 47(5):507–516.
   PubMed Web of Science ®Google Scholar